Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsets

13 Jul 2023

Abstract excerpt

Rheumatoid arthritis (RA) is a common autoimmune disease. Janus kinase inhibitors (JAKi) have been approved for the treatment of RA; however, the impact of JAKi on immune cells remains inconclusive. This study investigated the response of immune cells to JAKi treatment to identify biomarkers by which to evaluate and predict clinical outcomes. Blood samples were collected from RA patients before and after JAKi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to Rheumatoid Arthritis Research and Therapies
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37439387
DOI: 10.1111/apm.13341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting the clinical efficacy of JAK inhibitor treatment for patients with rheumatoid arthritis based on Fas+ T cell subsetsPMID 37439387Read ↗

A Systems Immunology Approach Identifies Cytokine-Induced STAT Signaling Pathways Critical to Rheumatoid Arthritis Disease Activity and Treatment ResponseSemantic proximity Read ↗

Peripheral blood cellular dynamics of Rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugsSemantic proximity Read ↗

Vascular synovial phenotype indicates poor response to JAK inhibitors in rheumatoid arthritis patients: a pilot study.Semantic proximity Read ↗

Safety of JAK and IL-6 inhibitors in rheumatoid arthritis: a multicentor cohort studySemantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

Defining immune cell phenotypes that distinguish treatment responders and non-responders in RA.Semantic proximity Read ↗

Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritisSemantic proximity Read ↗

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.Semantic proximity Read ↗

Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritisSemantic proximity Read ↗

The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis.Semantic proximity Read ↗

Using protein microarray reveals clinical correlation between self-perception of patient and the apoptosis-related proteins in rheumatoid arthritisSemantic proximity Read ↗

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.